However, a phase III study revealed that retrovirus-based HSV-TK gene therapy did not generate significant clinical benefit for GBM patients compared with SOC treatment (mOS, 12.0 vs. 11.8 months; mPFS, 6.0 vs. 6.1 months) [158]. This evidence concerns the gene TKT and glioblastoma.